Obigen Pharma, Inc.
TTPEX:787670.70
TWD
-2.40
(-3.28%)
Obigen Pharma, Inc.
TPEX:7876
(Taipei Exchange)
Recent
price
70.70
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Obigen Pharma, Inc., a biopharmaceutical and contract development and manufacturing organization (CDMO), focuses on the discovery, development, manufacturing, and commercialization of specialized biologics and therapeutic solutions in Taiwan, the Asia-Pacific region, and international markets. The company operates through two core business segments: Biopharmaceutical Research and Development, and Contract Development and Manufacturing Services. Its service and product offerings encompass stable cell line development and cell banking; upstream microbial fermentation and mammalian cell culture processing; downstream purification process development and viral clearance validation; formulation development and stability testing programs; analytical characterization and method validation services; antibody-drug conjugate (ADC) linker-payload synthesis and bioconjugation technologies; recombinant protein and monoclonal antibody production; and current Good Manufacturing Practice (cGMP)-compliant aseptic liquid vial filling and packaging. Obigen Pharma, Inc. caters to commercial pharmaceutical companies, clinical-stage biotechnology enterprises, and biomedical research organizations. In recent operational developments, the company completed its registration and public listing on the Emerging Stock Board of the Taipei Exchange under ticker 7876, completed the commissioning of upgraded cGMP cleanroom suites and automated fill-finish lines to expand commercial-scale manufacturing capacity, secured strategic contract manufacturing and co-development alliances with regional biotechnology developers, and broadened its specialized ADC and bioconjugation platform capabilities to support preclinical and clinical-stage candidate pipelines. Obigen Pharma, Inc. was founded in 2021 and is headquartered in Taipei, Taiwan.